Methotrexate alone was not associated with reduced risk for AD, nor was use of a TNF blocker associated with additional lower risk adjusting for methotrexate prescription status beyond the benefit of etanercept or adalimumab alone (AOR 0.53 (0.37–0.76) and AOR 0.50 (0.32–0.78), Fig 8. The gene discussed is TNF; the disease is Alzheimer disease.